Abeona Therapeutics Secures $155 Million from Sale of Priority Review Voucher, Strengthening Financial Position Ahead of ZEVASKYN Launch
Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases, has officially closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million. The transaction was finalized on June 27, 2025, marking a significant financial milestone for the company.
The PRV was awarded by the U.S. Food and Drug Administration (FDA) in April 2025, in recognition of Abeona’s breakthrough therapy, ZEVASKYN™ (prademagene zamikeracel). ZEVASKYN is a first-in-class, autologous cell-based gene therapy approved for the treatment of wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and debilitating genetic skin disorder.
With the sale now completed, Abeona reports that its unaudited cash position — including cash, cash equivalents, restricted cash, and short-term investments — stood at approximately $225 million as of June 30, 2025. The proceeds from the PRV sale significantly bolster the company’s balance sheet and provide what leadership describes as a strong financial foundation for the next phase of growth.
“We have reached another key milestone: the successful sale of our PRV has closed,” said Joe Vazzano, Chief Financial Officer of Abeona. “The PRV proceeds, combined with our existing cash, provide Abeona with robust financial flexibility, ensuring over two years of operating capital for sustained growth without the need for further capital infusion — and that’s before factoring in ZEVASKYN sales.”
The company is preparing to initiate commercial treatments with ZEVASKYN in the third quarter of 2025 and anticipates achieving profitability by early 2026, according to Vazzano. The timing positions Abeona favorably in the gene therapy space, where high development costs often make long-term sustainability a challenge.
The FDA’s Priority Review Voucher program was established to incentivize the development of treatments for rare pediatric diseases by offering companies a valuable voucher upon approval of a qualifying therapy. These vouchers can significantly accelerate the regulatory review timeline for future drugs and are therefore highly sought after by large pharmaceutical companies — often commanding high sale prices, as demonstrated in this transaction.
Abeona’s successful monetization of the voucher is a strategic move that aligns with its broader mission: to bring transformative therapies to patients while maintaining a solid financial footing. The capital raised will support commercial operations, further development of the company’s gene therapy pipeline, and potentially new initiatives as it advances its leadership in the treatment of rare genetic skin disorders.
With a newly fortified cash position, an FDA-approved gene therapy, and commercial launch on the horizon, Abeona Therapeutics is now poised to transition from a development-stage company into a commercial player with long-term growth potential.
